5-year follow-up of ELEVATE-TN: acalabrutinib ± obinutuzumab vs. obinutuzumab + chlorambucil in TN CLL

Glossary: 17p: Chromosome 17p; AEs: Adverse events; BID: Twice a day; CI: Confidence interval; CLL: Chronic lymphocytic leukemia; CR: Complete response; CV: Cardiovascular; ECOG: Eastern Cooperation Oncology Group; HR: Hazard ratio; IRC: Independent Review Committee; NR: Not reached; ORR: Overall response rate; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; PO: Oral; TN: Treatment-naïve; PS: Performance status; TP53: Tomor protein 53

Get access to our exclusive articles.